What do systematic reviews say?

Glycerol laxative vs acupuncture

The review found no eligible studies for this question.

• Pharmacological treatment for antipsychotic‐related constipation 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mannitol vs phenolphthalein or rhubarb soda

The review found no eligible studies for this question.

• Pharmacological treatment for antipsychotic‐related constipation 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adjunctive antioxidants for schizophrenia vs placebo

Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).

• Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.73 [0.48, 1.11]
  16 studies · 1584 participants
  Moderate

Adjunct cognitive behavioural therapy vs adjunct supportive psychotherapy

Adjunct cognitive behavioural therapy showed no clear difference in adverse event: Leaving the study early compared with adjunct supportive psychotherapy (moderate certainty).

• Treatments for delusional disorder 2015 · Cochrane Headline outcomes only
  RR 0.17 [0.02, 1.18]
  1 study · 24 participants
  Moderate

HALOPERIDOL vs first‐generation antipsychotics

Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.87, 1.24]
  28 studies · 1299 participants
  Low

HALOPERIDOL vs first‐generation antipsychotics

It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1 [0.42, 2.35]
  16 studies · 640 participants
  Very low

HALOPERIDOL vs first‐generation antipsychotics

It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  RR 1.02 [0.75, 1.38]
  2 studies · 137 participants
  Very low

HALOPERIDOL vs first‐generation antipsychotics

• Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

SPECIALISED TEAM vs usual care

SPECIALISED TEAM probably leads to lower compliance with treatment ‐ treatment stopped in spite of need ‐ by… compared with STANDARD CARE (moderate certainty).

• Early intervention for psychosis 2011 · Cochrane Headline outcomes only
  RR 0.2 [0.1, 0.42]
  1 study · 507 participants
  Moderate

SPECIALISED TEAM vs usual care

SPECIALISED TEAM showed no clear difference in compliance with treatment ‐ treatment stopped in spite of need ‐ by… compared with STANDARD CARE (moderate certainty).

• Early intervention for psychosis 2011 · Cochrane Headline outcomes only
  RR 0.66 [0.29, 1.5]
  1 study · 436 participants
  Moderate

Beta‐blockers vs placebo

Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).

• Beta‐blocker supplementation of standard drug treatment for schizophrenia 2001 · Cochrane Headline outcomes only
  RR 1.62 [0.92, 2.83]
  8 studies · 274 participants
  Low